EUVIMEDEUVIMED entdecken
Crossref

A novel ionizable lipid with comprehensive improvements in transfection potency, immune profile and safety of lipid nanoparticle

Kun Guo, Lingling Bu, Jintong Du, Wei Zhang, Jiayuan Xia, Mengmeng Tao, Xianyu Shao, Lijing Liu, Weijun Zhao, Yunsong Cai, Yong Yang, Xuben Hou und 1 weitere

Journal of Controlled Release · 2025-10 · 386 · 114126

DOI: 10.1016/j.jconrel.2025.114126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-10. Verfasst von Kun Guo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Innovation Center for Nucleic Acid Medicine, Wuxi Research Center for Innovative Medicines and Life Health, China Pharmaceutical University, Wuxi 214…. Hauptthemen laut MEDLINE: Nanoparticles, Lipids, RNA, Messenger. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Shuangchuang Program of Jiangsu Province, Graduate Research and Innovation Projects of Jiangsu Province, High Level Innovation and Entrepreneurial Research Team Program in Jiangsu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ionizable cationic lipid is critical for construction of lipid nanoparticles (LNPs) for mRNA delivery. Here, we reported the rational design and evaluation of FS01, a novel ionizable cationic lipid incorporating an ortho-butylphenyl-modified hydrophobic tail into a squaramide-based lipid headgroup architecture. Molecular dynamics simulations revealed that FS01 enhances mRNA stability through π-π stacking interactions between its aromatic tail and nucleobases aromatic rings, alongside hydrogen bonding via the squaramide headgroup. FS01-LNPs demonstrated smaller particle sizes (∼ 70 nm), high encapsulation efficiency (> 90 %), and superior mRNA delivery performance across intramuscular, subcutaneous, and intravenous routes in mice compared to FDA-approved lipids (Dlin-MC3-DMA, SM-102, ALC-0315). In prophylactic vaccine models (Varicella-zoster virus and Hepatitis B virus), FS01-LNP formulations elicited robust antigen-specific antibodies, memory B cells, and Th1-biased T cell responses, outperforming benchmark LNPs. Further, transcriptomic profiling and safety assessments demonstrated that FS01-LNP induced a well-balanced innate immune activation with minimal inflammation and liver toxicity, contrasting with the pronounced reactogenicity of Dlin-MC3-DMA and ALC-0315 LNPs. These findings highlighted FS01 as a promising ionizable lipid candidate for mRNA therapeutics, offering enhanced delivery efficiency, immunogenicity, and safety, with potential applications extending beyond vaccines to gene editing and protein replacement therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesLipidsRNA, MessengerAnimalsFemaleTransfectionMiceMice, Inbred C57BLHumansMice, Inbred BALB CLiposomes

Stichwörter der Autor:innen

ImmunogenicityInflammationIonizable cationic lipidLipid nanoparticleReactogenicityΠ-π stacking interaction

Substanzen

LipidsRNA, MessengerLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Innovation Center for Nucleic Acid Medicine, Wuxi Research Center for Innovative Medicines and Life Health, China Pharmaceutical University, Wuxi 214000, China; Center for Infectious Medicine and Vaccine Research, Schoo…
  • Center for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China; Institute of Translational Medicine, China Pharmaceutical Univ…
  • Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250012, China.
  • Institute of Translational Medicine, China Pharmaceutical University, Nanjing 211198, China; Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.
  • Firestone Biotechnologies, Shanghai 200003, China. Electronic address: caiyunsong@outlook.com.
  • Institute of Translational Medicine, China Pharmaceutical University, Nanjing 211198, China; Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China. Electronic address…

Förderung

  • Shuangchuang Program of Jiangsu Province
  • Graduate Research and Innovation Projects of Jiangsu Province
  • High Level Innovation and Entrepreneurial Research Team Program in Jiangsu
  • Shandong Province Natural Science Foundation
  • National Natural Science Foundation of China
  • Shandong Talents Team Cultivation Plan of University Preponderant Discipline
  • China Pharmaceutical University
  • Chinese Center for Disease Control and Prevention

Zitieren

APA

Guo, K., Bu, L., Du, J., Zhang, W., Xia, J., Tao, M., Shao, X., Liu, L., Zhao, W., Cai, Y., Yang, Y., Hou, X., & Lin, A. (2025). A novel ionizable lipid with comprehensive improvements in transfection potency, immune profile and safety of lipid nanoparticle. Journal of Controlled Release, 386, 114126. https://doi.org/10.1016/j.jconrel.2025.114126

Vancouver

Guo K, Bu L, Du J, Zhang W, Xia J, Tao M, et al. A novel ionizable lipid with comprehensive improvements in transfection potency, immune profile and safety of lipid nanoparticle. Journal of Controlled Release. 2025;386:114126. doi:10.1016/j.jconrel.2025.114126

BibTeX
@article{Guo2025,
  author = {Guo, Kun and Bu, Lingling and Du, Jintong and Zhang, Wei and Xia, Jiayuan and Tao, Mengmeng and Shao, Xianyu and Liu, Lijing and Zhao, Weijun and Cai, Yunsong and Yang, Yong and Hou, Xuben and Lin, Ang},
  title = {A novel ionizable lipid with comprehensive improvements in transfection potency, immune profile and safety of lipid nanoparticle},
  journal = {Journal of Controlled Release},
  year = {2025},
  volume = {386},
  pages = {114126},
  doi = {10.1016/j.jconrel.2025.114126}
}
Kostenlos starten →